<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacogenomics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacogenomics</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Pharmacogenomics</journal-title></journal-title-group><issn pub-type="ppub">1462-2416</issn><issn pub-type="epub">1744-8042</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4551460</article-id><article-id pub-id-type="pmcid-ver">PMC4551460.1</article-id><article-id pub-id-type="pmcaid">4551460</article-id><article-id pub-id-type="pmcaiid">4551460</article-id><article-id pub-id-type="manuscript-id">NIHMS715030</article-id><article-id pub-id-type="pmid">23837482</article-id><article-id pub-id-type="doi">10.2217/pgs.13.81</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS715030</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA715030</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Pharmacogenomics in early-phase clinical development</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Burt</surname><given-names initials="T">Tal</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dhillon</surname><given-names initials="S">Savita</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Scientfic Director, Duke Global Proof-of-Concept (POC) Research Network, Duke Clinical Research Unit (DCRU) &amp; Duke Clinical Research Insttute (DCRI); Assistant Professor, Department of Psychiatry and Behavioral Sciences, Duke University, Box 3854, Durham, NC 27710, USA</aff><aff id="A2"><label>2</label>Medical Director, Medanta Duke Research Insttute (MDRI), Medanta, The Medicity, Sector &#8211; 38, Gurgaon, Haryana 122 001, India</aff><author-notes><corresp id="cor1"><label>*</label>Author for correspondence: <email>tal.burt@duke.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2013</year></pub-date><volume>14</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">257058</issue-id><fpage>1085</fpage><lpage>1097</lpage><pub-history><event event-type="nihms-submitted"><date><day>14</day><month>08</month><year>2015</year></date></event><event event-type="pmc-release"><date><day>27</day><month>08</month><year>2015</year></date></event><event event-type="pmc-live"><date><day>28</day><month>08</month><year>2015</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-05 14:06:38.133"><day>05</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms715030.pdf"/><abstract><p id="P1">Pharmacogenomics (PGx) offers the promise of utilizing genetic fingerprints to predict individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase clinical trial PGx applications can identify human genome variations that are meaningful to study design, selection of participants, allocation of resources and clinical research ethics. Results can inform later-phase study design and pipeline developmental decisions. Nevertheless, our review of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> database demonstrates that PGx is rarely used by drug developers. Of the total 323 trials that included PGx as an outcome, 80% have been conducted by academic institutions after initial regulatory approval. Barriers for the application of PGx are discussed. We propose a framework for the role of PGx in early-phase drug development and recommend PGx be universally considered in study design, result interpretation and hypothesis generation for later-phase studies, but PGx results from underpowered studies should not be used by themselves to terminate drug-development programs.</p></abstract><kwd-group><kwd>clinical research</kwd><kwd>drug development</kwd><kwd>early-phase</kwd><kwd>PD</kwd><kwd>PGt</kwd><kwd>PGx</kwd><kwd>pharmacodynamics</kwd><kwd>pharmacogenetics</kwd><kwd>pharmacogenomics</kwd><kwd>pharmacokinetics</kwd><kwd>PK</kwd><kwd>POC</kwd><kwd>proof-of-concept</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>